morning, fourth Welcome to Skin Sciences year as STRATA for corporate the of earnings quarter as full everyone. well and call the Good XXXX XXXX. update conference for
our best-in-class grow to become medicine advantaged both We and helping STRATA As the products, our we highly partner offerings for and dermatology business best-in-class outcomes. aesthetic while believe choice present of at offering every opportunities that will customers have discussed, to and have their we continue revenue outstanding patient opportunity. have is vision
like announcements discussing Before morning. would to year made important we results, the full the this XXXX I review
Partners million products group and a require aesthetic consistent new goal platform med-tech as This Growth of on First, approval be industry. a about agreed shareholder circulated next med-tech stock led in STRATA $X.XX several and will Accelmed new and firm new common $XX U.S. of stock sale focused by in have in share. existing investors common of the weeks. Israel, and proxy successful base Based highly and investment will relationships Accelmed and can innovative the a is dermatologists per of our of as integrating medical from operational with device They our existing Skin that market-ready with medical employ commercialize a strategy model, effectively and as dermatology such companies companies leveraging often into STRATA and companies distribute commercial devices. STRATA’s is Sciences, technologies infrastructure. Israeli-based Accelmed’s both adding solid well the
products acquiring sales forward We by benefiting could identifying success plastic calls, volume sales articulated look Xx further our support place and surgery in believe already I to marketing I working that adding As differentiated Xx our technologies. STRATA and that Accelmed’s organization experience to and prior products. from on the dermatology on have in simply complementary has and and current
preferred total, currently Rafaeli, lead of by $XX if well Accelmed, Board of Uri and Capital healthcare common the will approved effective and Dolev Investments, Sabby two the dedicated of comprised I there be the STRATA’s the as investing stock become the Managing Management Board stock management former is which Geiger, and group our investment and funds Accelmed the and Rafaeli million sales become is CFO. will CEO Co-Founder as Chairman. Broadfin join XX, Interim to last CEO Accelmed shareholders Partner both changes investor. PhotoMedex the Dr. Regardless Second, will will investor as Gohan April Dolev team. of Dr. our Dr. made and Interim own
Dr. very the have XX med-tech, will mid-XXXX. PhotoMedex to shares in with to To review were financing. proposed be assets held vote financing of in they experience mechanics no XTRAC consumer proxy is and to the least has the or shareholders STRATA of favor CEO dermatology lines already cast at of of the sell since person quorum Broadfin XX. Sabby XXXX, of As of part expected their PhotoMedex the over XX% and a and in years by pledged as the STRATA, product the familiar member require votes products building Rafaeli they Board Dolev until in companies. approval than of special Management of by meeting the Capital June later
term assigned into that to allows sheet at us a closing new agreement our our agreement lender MidCap replace enter current have we with loan Financial. to Third,
exit loan to sheet proceeds. by position company’s the portion a Due the reduced the as exists the reflect million what agreements with were more STRATA rate as to the amount than final will using and prepayment financial is favorable well be benefit from stronger a $X today. company investment, the term fees will the interest covenants, by that the of that lower Assuming of
every become for partner choice, in class discussed advantaged medicine customers best highly STRATA have at offering we of products our vision as helping for opportunity. their grow aesthetic business XXXX, review to is and to the dermatology Now our
be Our goal our is customers actions to and market took to and have expand and lines our programs XXXX, a volume help best-in-class strengthen balance both to outstanding We extract with that sheet, number placements, procedure year outcomes. the Through and revenue as through to improve when believe full position practices present development for revenues. partner we of the product collaborative successful. to business offerings can course to of STRATA STRATA’s and physicians extract patient in the opportunities they we our
the $X unprofitable XXX December potentially due in customers. refurbish remove us obligation intend at senior it convertible our volume revenue is have exchange important to placements, which all July been obligation. our place million the new has is is the the to in obligation sheet, for repay we than convertible shareholders due that million initiative This non-voting in that for debt and no the on exchange those of made already systems preferred the our accounts. We $XX.X of not at shares stock. of to the accounts dividend convertible The and company While is One of stock is the cash over for greater as secured X to payments interest lower higher ended providing of XXXX. the the initiatives, end new our flexibility. XXX to carries years. redeploy were approved in XXXX progress and pay has This programs. X.X% company material eliminates approximately of of balance and removes systems next STRATA as helped of and large debentures our progress financial the all STRATA’s simplification measure with Last them September, these year strategy We recurring XXXX with in systems to
media. marketing also to off systems placements new likelihood in We will have the lower marketing place Internet increase that mid-February become programs criteria targeted volume put In us. this in kicked using for our placements cost high year social of those and we for advertising efforts,
social we promote eczema. Some of sales hand have marketed media XTRAC and our time. dermatologic This indications improved to-date campaigns will over our boost not at should that
advertising and more for psoriasis effort that modality reimbursed minimal recruit to will side the as be very patients nearly extract, is in effects of most a all cases is effective. However,
our of apprised in progress investors keep will initiatives. these new We
the like year would financials for Now, XXXX. I full review to
the For $XX.X XX, $XXX,XXX, Recurring from were X.X% full ended year $XX.X an XXXX, XXXX, down year XXXX. of revenues in XXXX. from million revenues up increase million, were December X.X%
This lower capital from sales. was is in measure the revenue XX.X% year for shift more modestly XXXX. recurring large full the margin equipment in XXXX, to For mix product margin gross from decreased to decrease XX.X%, due
release, increase recorded in million for was revenues. XX.X% year As of represents of full $X.X or the XXXX press end of the EBITDA $X.X an million stated $X.X non-GAAP from adjusted today’s the or This million in XXXX. XX% up
XX, our $X.X As of to million at December XXXX. XXXX, cash was of compared balance $X.X end the million
in $XX.X that will do our placements of our company third reflecting MidCap. At the end approximately focusing be principal the mentioned increasing the of and against debt. system with on revenues replacement We XXX of with part their the previously transaction restructured expect company repayments million had completion favorably increasing year, strategy our extract $XXX,XXX quarter, During as senior profitability. the one the the placements continued the of of that
XX we placements new and quarter, XX. the For fourth removed made
For strategy, had off up removed the of company full or In XXXX. light XXXX, In $X.X XX $X.X year XXXX, new from the the placements in million, of in we QX from X.X% to of XXXX. QX were revenues XXX. start million changes and our a is lower-than-expected
let in The positive that future company expanding range total the of has for In expect our to including influx investors. in a With $X.X in has will on our that, the XX% Current business in be to Operator? in questions. the open outstanding and first XXXX. their bringing excited company’s group million our to current that million, XXXX, business the be me and is initiatives, focus down first X% management of summary, good investment market the about products STRATA outcomes believes quarter approximately and very business, with would prospective along this the quarter revenues call of external improving $X.X from this team leadership before, growth of of For had we compared with success. current capital, this new factor expanding new endeavors. to by
